Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984;13(2):106-8.
doi: 10.1007/BF00257124.

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

S G Allan, A Gregor, M A Cornbleet, R C Leonard, J F Smyth, I W Grant, G K Crompton

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

S G Allan et al. Cancer Chemother Pharmacol. 1984.

Abstract

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR 17%) were seen in patients with limited and extensive disease, respectively. Time to relapse was short in those responding (4-4.5 months), and most responders required additional treatments. The overall toxicity was minimal and patient compliance was high. This combination is useful for the palliative treatment of small cell lung cancer when aggressive chemotherapy is inappropriate.

PubMed Disclaimer

References

    1. Cancer Chemother Pharmacol. 1982;7(2-3):187-93 - PubMed
    1. Cancer Treat Rep. 1977 May-Jun;61(3):333-42 - PubMed
    1. Cancer Treat Rev. 1980 Sep;7 Suppl 1:65-70 - PubMed
    1. Cancer. 1976 Dec;38(6):2201-7 - PubMed
    1. Cancer Treat Rev. 1980 Sep;7 Suppl 1:59-63 - PubMed

LinkOut - more resources